XML 40 R23.htm IDEA: XBRL DOCUMENT
v3.25.1

BASIC AND DILUTED NET LOSS PER SHARE | 12 Months Ended
--- | ---
Dec. 31, 2024
Earnings Per Share [Abstract] |
BASIC AND DILUTED NET LOSS PER SHARE | NOTE 11 - BASIC AND DILUTED NET LOSS PER SHARE The basic and diluted net loss per share and weighted average number of shares of common stock used in the calculation of basic and diluted net loss per share were presented in the consolidated statements of comprehensive loss for the years ended December 31, 2024 and 2023. In the calculation of the basic and diluted net loss, the Company included warrants that would be exercised for no or little consideration and are exercisable with no contingencies. Due to the net loss to common shareholders in each of the periods presented above, diluted loss per share was computed without consideration to potentially dilutive instruments as their inclusion would have been anti-dilutive. As of December 31, 2024 and 2023, potentially dilutive securities excluded from the diluted loss per share calculation are as follows: SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES EXCLUDED FROM DILUTED LOSS PER SHARE
|  | For the Years Ended December 31, |
|  | 2024 |  |  | 2023 |
Series A warrants October 2022 |  |  | - |  |  |  | 1,022,495 |
Warrant to underwriters October 2022 |  |  | 51,125 |  |  |  | 51,125 |
Warrant to underwriters May 2023 |  |  | 32,778 |  |  |  | 32,778 |
Warrant to underwriters May 2023 |  |  | 60,476 |  |  |  | 60,476 |
Warrant to underwriters June 2023 |  |  | 35,088 |  |  |  | 35,088 |
Warrant series C June 2023 |  |  | - |  |  |  | 350,878 |
Warrant to underwriters June 2023 |  |  | 31,231 |  |  |  | 31,231 |
Warrant series D June 2023 |  |  | - |  |  |  | 312,309 |
Warrant series E January 2024 |  |  | 1,685,682 |  |  |  | - |
Warrant to underwriters January 2024 |  |  | 84,284 |  |  |  | - |
Warrant series F June 2024 |  |  | 3,133,338 |  |  |  | - |
Warrant to underwriters June 2024 |  |  | 78,333 |  |  |  | - |
Outstanding employee stock options to purchase common stock |  |  | 2,497,366 |  |  |  | 2,095,362 |
Potentially dilutive securities excluded from diluted loss per share |  |  | 2,584,991 |  |  |  | 2,095,362 |
MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration